102 results
424B3
SYRE
Spyre Therapeutics Inc.
15 May 24
Prospectus supplement
4:06pm
and elsewhere in this Quarterly Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
from time to time with the Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment
POS AM
5ry4e
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
424B3
qpov7u8xrqqbj xkz
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
fw8oer
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
bnebw
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
uj6s2rra
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
4v5ieua1e9svob3jk
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
vpnyr gz8w0
6 Feb 24
Prospectus supplement
9:37pm
8-K
jalr905u ieow
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
EX-14.1
1zb3fzy9su
5 Feb 24
Entry into a Material Definitive Agreement
7:36am